Citations (99)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Ayaka Inada, Keiko Hosohata, Saki Oyama, Iku Niinomi, Yasuhiro Mori, Yuki Yamaguchi, Mayako Uchida & Kazunori Iwanaga. (2019) Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database. Therapeutics and Clinical Risk Management 15, pages 59-64.
Read now
Read now
Vittorio Fusco, Daniele Santini, Grazia Armento, Giuseppe Tonini & Giuseppina Campisi. (2016) Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology. Expert Opinion on Drug Safety 15:7, pages 925-935.
Read now
Read now
Alexander C Small & William K Oh. (2012)
Bevacizumab treatment of prostate cancer. Expert Opinion on Biological Therapy 12:9, pages 1241-1249.
Read now
Read now
P. Hadji. (2011) Managing bone health with zoledronic acid: a review of randomized clinical study results. Climacteric 14:3, pages 321-332.
Read now
Read now
Bevin C English, Caitlin E Baum, David E Adelberg, Tristan M Sissung, Paul G Kluetz, William L Dahut, Douglas K Price & William D Figg. (2010) A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Therapeutics and Clinical Risk Management 6, pages 579-583.
Read now
Read now
Andrea L Harzstark & Eric J Small. (2010) Castrate-resistant prostate cancer: therapeutic strategies. Expert Opinion on Pharmacotherapy 11:6, pages 937-945.
Read now
Read now
Athanassios Kyrgidis, Stefanos Triaridis, Kostantinos Vahtsevanos & Kostantinos Antoniades. (2009) Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients. Expert Review of Anticancer Therapy 9:8, pages 1125-1134.
Read now
Read now
Articles from other publishers (92)
Siti Salmiah Mohd Yunus, Hui Yuh Soh, Mariati Abdul Rahman, Xin Peng, Chuanbin Guo & Roszalina Ramli. (2023) MicroRNA in medication related osteonecrosis of the jaw: a review. Frontiers in Physiology 14.
Crossref
Crossref
Hardeep S. Ahdi, Thomas Adam Wichelmann, Sasirekha Pandravada & Eli D. Ehrenpreis. (2023) Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS). BMC Pharmacology and Toxicology 24:1.
Crossref
Crossref
Janson Trieu, Mark Chang, Vanessa Rojas, Neilmegh Varada, Yen Cao, Michael Anderson & Nicholas J. Vogelzang. (2022) Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents: A Real-World Analysis. Clinical Genitourinary Cancer 20:5, pages 399-403.
Crossref
Crossref
Isti Rahayu Suryani, Iraj Ahmadzai, Sohaib Shujaat, Hongyang Ma & Reinhilde Jacobs. (2022) Non-antiresorptive drugs associated with the development of medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. Clinical Oral Investigations 26:3, pages 2269-2279.
Crossref
Crossref
Antoine Yanni, Cyril Bouland, Raquel Monteiro, Alexandra Rodriguez, Isabelle Loeb, Rokneddine Javadian & Didier Dequanter. (2022) Contribution of antiangiogenic agents to the risk of medication-related osteonecrosis of the jaw in combination with antiresorptive agents: Preliminary results in a comparative prospective report of 59 oncologic cases. Journal of International Society of Preventive and Community Dentistry 12:5, pages 564.
Crossref
Crossref
Ceren Bilgilier, Thorsten Fuereder, Marie-Theres Kastner, Zoltan Vass, Ingeborg Brandl, Hanka Sahbegovic, Christian F. Singer & Christoph Steininger. (2022) Oral Abundance of <b><i>Actinomyces</i></b> spp. in Breast Cancer Patients. Oncology 100:4, pages 221-227.
Crossref
Crossref
Catherine Van Poznak, Evan L. Reynolds, Cherry L. Estilo, Mimi Hu, Bryan Paul Schneider, Daniel L. Hertz, Christina Gersch, Jacklyn Thibert, Dafydd Thomas, Mousumi Banerjee, James M. Rae & Daniel F. Hayes. (2020) Osteonecrosis of the jaw risk factors in bisphosphonate‐treated patients with metastatic cancer. Oral Diseases 28:1, pages 193-201.
Crossref
Crossref
Akanksha Srivastava, Graciela M. Nogueras Gonzalez, Yimin Geng, Alexander M. Won, Jeffrey Myers, Yisheng Li & Mark S. Chambers. (2021) Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-Analysis. Journal of Immunotherapy and Precision Oncology 4:4, pages 196-207.
Crossref
Crossref
Salvatore D’Amato, Antonio Troiano, Giorgio Lo Giudice, Davide De Cicco, Mario Rusciano, Gianpaolo Tartaro & Giuseppe Colella. (2021) Resective Surgery versus Debridement in Stage 2 Medication-Related Osteonecrosis of the Jaw. Applied Sciences 11:18, pages 8553.
Crossref
Crossref
Benjie Law, Hui Yuh Soh, Syed Nabil, Rama Krsna Rajandram, Abd Jabar Nazimi & Roszalina Ramli. (2021) Autologous Platelet-Rich Fibrin (PRF) as an Adjunct in the Management of Osteoradionecrosis and Medication-Related Osteonecrosis of Jaws. Case Series in A Single Centre. Applied Sciences 11:8, pages 3365.
Crossref
Crossref
Marcelo Vieira da Costa Almeida, Antonio C. Moura, Lúcia Santos, Luciana Gominho, Ully Dias Nascimento Távora Cavalcanti & Kaline Romeiro. (2021) Photodynamic Therapy as an adjunct in the Treatment of Medication-Related Osteonecrosis of the Jaw: A Case Report. Journal of Lasers in Medical Sciences 12:1, pages e12-e12.
Crossref
Crossref
J.G. Messer, E.J. Castillo, A.M. Abraham, J.M. Jiron, R. Israel, J.F. Yarrow, S. Thomas, M.C. Reynolds, R.D. Wnek, M. Jorgensen, N. Wanionok, C. Van Poznak, I. Bhattacharyya, D.B. Kimmel & J.I. Aguirre. (2020) Anti-vascular endothelial growth factor antibody monotherapy causes destructive advanced periodontitis in rice rats (Oryzomys palustris). Bone 130, pages 115141.
Crossref
Crossref
Noam Yarom, Charles L. Shapiro, Douglas E. Peterson, Catherine H. Van Poznak, Kari Bohlke, Salvatore L. Ruggiero, Cesar A. Migliorati, Aliya Khan, Archie Morrison, Holly Anderson, Barbara A. Murphy, Devena Alston-Johnson, Rui Amaral Mendes, Beth Michelle Beadle, Siri Beier Jensen & Deborah P. Saunders. (2019) Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. Journal of Clinical Oncology 37:25, pages 2270-2290.
Crossref
Crossref
Cesar A Migliorati, Michael T Brennan & Douglas E Peterson. (2019) Medication-Related Osteonecrosis of the Jaws. JNCI Monographs 2019:53.
Crossref
Crossref
Z. Mihaylova, R. Ugrinov, E. Aleksiev & P. Stanimirov. (2019) Osteonecrosis of the Jaws in Patients Receiving Anti-Angiogenic Drugs and Chemotherapeutics: Literature Review and Case Reports. Acta Medica Bulgarica 46:2, pages 51-56.
Crossref
Crossref
Edit Veszelyné Kotán, Tímea Bartha-Lieb, Zsolt Parisek, Attiláné Meskó, Mihály Vaszilkó & Balázs Hankó. (2019) Database analysis of the risk factors of bisphosphonate-related osteonecrosis of the jaw in Hungarian patients. BMJ Open 9:5, pages e025600.
Crossref
Crossref
Antonio Fabrizio Nifosì, Mariateresa Zuccarello, Lorenzo Nifosì, Vanessa Hervas Saus & Gianfilippo Nifosì. (2019) Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology. Journal of the Korean Association of Oral and Maxillofacial Surgeons 45:1, pages 3.
Crossref
Crossref
Pınar Kubilay Tolunay, Hatime Arzu Yaşar, Güngör Utkan & Yüksel Ürün. (2018) Osteonecrosis of the jaw with sunitinib and zoledronic acid combination: A case report. Journal of Oncological Sciences 4:2, pages 116-118.
Crossref
Crossref
Estee L. George, Yi-Ling Lin & Marnie M. Saunders. (2018) Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective. Bone Reports 8, pages 104-109.
Crossref
Crossref
Badr Al-Jandan, Hesham F. Marei, Hatem Abuohashish, Osama Zakaria & Haytham Al-Mahalawy. (2018) Effects of sunitinib targeted chemotherapy on the osseointegration of titanium implants. Biomedicine & Pharmacotherapy 100, pages 433-440.
Crossref
Crossref
Miriam Hegemann, Jens Bedke, Arnulf Stenzl & Tilman Todenhöfer. (2017) Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience. Therapeutic Advances in Urology 9:3-4, pages 81-88.
Crossref
Crossref
Andrea Szabó, Ágnes Janovszky, Levente Pócs & Mihály Boros. (2017) The periosteal microcirculation in health and disease: An update on clinical significance. Microvascular Research 110, pages 5-13.
Crossref
Crossref
Petra Rugani, Christian Walter, Barbara Kirnbauer, Stephan Acham, Yvonne Begus-Nahrman & Norbert Jakse. (2016) Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma. Dentistry Journal 4:4, pages 32.
Crossref
Crossref
Guenter Russmueller, Rudolf Seemann, Kathrin Weiss, Victoria Stadler, Manuel Speiss, Christos Perisanidis, Thorsten Fuereder, Birgit Willinger, Irene Sulzbacher & Christoph Steininger. (2016) The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection. Scientific Reports 6:1.
Crossref
Crossref
Shady Abu-Sirhan, Moritz Hertel, Saskia Preissner, Henrik Carl Wirtz, Sascha Rudolf Herbst, Philipp Pierdzioch, Jan D. Raguse & Stefan Hartwig. (2016) Bactericidal efficacy of cold plasma in processed bone. A new approach for adjuvant therapy of medication-related osteonecrosis of the jaw?. Clinical Plasma Medicine 4:1, pages 9-13.
Crossref
Crossref
V. Patel, M. Kelleher, C. Sproat, J. Kwok & M. McGurk. (2015) New cancer therapies and jaw necrosis. British Dental Journal 219:5, pages 203-207.
Crossref
Crossref
Rachelle W. Johnson, Ernestina Schipani & Amato J. Giaccia. (2015) HIF targets in bone remodeling and metastatic disease. Pharmacology & Therapeutics 150, pages 169-177.
Crossref
Crossref
A. Peer & M. Khamaisi. (2014) Diabetes as a Risk Factor for Medication-Related Osteonecrosis of the Jaw. Journal of Dental Research 94:2, pages 252-260.
Crossref
Crossref
Kyoung Min KimYumie RheeYong-Dae KwonTae-Geon KwonJeong Keun LeeDeog-Yoon Kim. (2015) Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. Journal of Bone Metabolism 22:4, pages 151.
Crossref
Crossref
J. Hernández Reyna & J.R. Aguilera Pérez. (2015) Papel de los bisfosfonatos en la osteonecrosis mandibular. Perinatología y Reproducción Humana 29:1, pages 26-29.
Crossref
Crossref
Matthias Troeltzsch, Markus Troeltzsch, Christoph Pache & Timothy Woodlock. 2015. Medication-Related Osteonecrosis of the Jaws. Medication-Related Osteonecrosis of the Jaws
193
200
.
Aliya A Khan, Archie Morrison, David A Hanley, Dieter Felsenberg, Laurie K McCauley, Felice O'Ryan, Ian R Reid, Salvatore L Ruggiero, Akira Taguchi, Sotirios Tetradis, Nelson B Watts, Maria Luisa Brandi, Edmund Peters, Teresa Guise, Richard Eastell, Angela M Cheung, Suzanne N Morin, Basel Masri, Cyrus Cooper, Sarah L Morgan, Barbara Obermayer-Pietsch, Bente L Langdahl, Rana Al Dabagh, K. Shawn Davison, David L Kendler, George K Sándor, Robert G Josse, Mohit Bhandari, Mohamed El Rabbany, Dominique D Pierroz, Riad Sulimani, Deborah P Saunders, Jacques P Brown & Juliet Compston. (2015) Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus. Journal of Bone and Mineral Research 30:1, pages 3-23.
Crossref
Crossref
Ágnes Janovszky, Tamás Vereb, Andrea Szabó & József Piffkó. (2014) Current approaches for early detection and treatment of medication-related osteonecrosis of jaw. Orvosi Hetilap 155:49, pages 1960-1966.
Crossref
Crossref
Masahiro Nozawa, Takeshi Inagaki, Kazuhiro Nagao, Tsukasa Nishioka, Takahiro Komura, Atsunobu Esa, Michio Kitagawa, Masaaki Imanishi, Yasunari Uekado, Takatoshi Ogawa, Hiroshi Kajikawa, Shigeya Uejima, Hideyasu Matsuyama, Isao Hara & Hirotsugu Uemura. (2013) Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis. International Journal of Clinical Oncology 19:4, pages 693-701.
Crossref
Crossref
D. Pakosch, D. Papadimas, J. Munding, D. Kawa & M.S. Kriwalsky. (2014) Medikamenteninduzierte KomplikationenDrug-induced complications. Der MKG-Chirurg 7:2, pages 133-136.
Crossref
Crossref
Jamal Zekri, Maged Mansour & Syed Mustafa Karim. (2014) The anti-tumour effects of zoledronic acid. Journal of Bone Oncology 3:1, pages 25-35.
Crossref
Crossref
Giuseppina CampisiStefano Fedele, Vittorio Fusco, Giuseppe Pizzo, Olga Di Fede & Alberto Bedogni. (2014) Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncology 10:2, pages 257-275.
Crossref
Crossref
Benjamin A. Gartrell, Robert E. Coleman, Karim Fizazi, Kurt Miller, Fred Saad, Cora N. Sternberg & Matthew D. Galsky. (2014) Toxicities Following Treatment with Bisphosphonates and Receptor Activator of Nuclear Factor-κB Ligand Inhibitors in Patients with Advanced Prostate Cancer. European Urology 65:2, pages 278-286.
Crossref
Crossref
Shinichiro Kuroshima, Rodan B. Mecano, Ryuichiro Tanoue, Kiyono Koi & Junro Yamashita. (2014) Distinctive Tooth-Extraction Socket Healing: Bisphosphonate Versus Parathyroid Hormone Therapy. Journal of Periodontology 85:1, pages 24-33.
Crossref
Crossref
Simonetta Franco, Simona Miccoli, Luisa Limongelli, Angela Tempesta, Giorgio Favia, Eugenio Maiorano & Gianfranco Favia. (2014) New Dimensional Staging of Bisphosphonate-Related Osteonecrosis of the Jaw Allowing a Guided Surgical Treatment Protocol: Long-Term Follow-Up of 266 Lesions in Neoplastic and Osteoporotic Patients from the University of Bari. International Journal of Dentistry 2014, pages 1-10.
Crossref
Crossref
Carlos Pigrau-Serrallach, Evelyn Cabral-Galeano, Benito Almirante-Gragera, Roger Sordé-Masip, Dolors Rodriguez-Pardo, Nuria Fernandez-Hidalgo, Nieves Larrosa-Escartín, Socorro Bescos-Atín & Albert Pahissa-Berga. (2014) Long-term follow-up of jaw osteomyelitis associated with bisphosphonate use in a tertiary-care center. Enfermedades Infecciosas y Microbiología Clínica 32:1, pages 18-22.
Crossref
Crossref
Géraldine Lescaille, Amélie E. Coudert, Vanessa Baaroun, Agnès Ostertag, Emmanuel Charpentier, Marie-José Javelot, Rafael Tolédo, Patrick Goudot, Jean Azérad, Ariane Berdal, Jean-Philippe Spano, Blandine Ruhin & Vianney Descroix. (2014) Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients. Bone 58, pages 103-107.
Crossref
Crossref
Thomas E. Merchant & Susan R. Rose. 2014. ALERT • Adverse Late Effects of Cancer Treatment. ALERT • Adverse Late Effects of Cancer Treatment
49
81
.
Matthew S. Epstein, Hillel D. Ephros & Joel B. Epstein. (2013) Review of current literature and implications of RANKL inhibitors for oral health care providers. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 116:6, pages e437-e442.
Crossref
Crossref
Daria Pakosch, Dimitrios Papadimas, Johanna Munding, Darafsch Kawa & Marcus Stephan Kriwalsky. (2012) Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab. Oral and Maxillofacial Surgery 17:4, pages 303-306.
Crossref
Crossref
Deborah Mukherji, Sally Temraz, David Wehbe & Ali Shamseddine. (2013) Angiogenesis and anti-angiogenic therapy in prostate cancer. Critical Reviews in Oncology/Hematology 87:2, pages 122-131.
Crossref
Crossref
Hani H. Mawardi, Nathaniel S. Treister & Sook‐Bin Woo. 2013. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism
929
940
.
Adam M. Brufsky, Susan M. Sereika, Aju Mathew, Onishi Tomifumi, Vikramjit Singh & Margaret Rosenzweig. (2013) Long-term Treatment with Intravenous Bisphosphonates in Metastatic Breast Cancer: A Retrospective Study. The Breast Journal, pages n/a-n/a.
Crossref
Crossref
Cesar A. Migliorati, Deborah Saunders, Michael S. Conlon, Hanne Kleven Ingstad, Paul Vaagen, Mitzi J. Palazzolo & Bente B. Herlofson. (2013) Assessing the association between bisphosphonate exposure and delayed mucosal healing after tooth extraction. The Journal of the American Dental Association 144:4, pages 406-414.
Crossref
Crossref
Iryna Kuchuk, Sasha Mazzarello, Kevin Butterfield, Anthony Appleton, Christina L. Addison & Mark Clemons. (2013) Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists. Journal of Bone Oncology 2:1, pages 38-46.
Crossref
Crossref
Joelle El-Amm & Jeanny B. Aragon-Ching. (2012) The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Therapeutic Advances in Medical Oncology 5:1, pages 25-40.
Crossref
Crossref
Joelle El-Amm, Ashley Freeman, Nihar Patel & Jeanny B. Aragon-Ching. (2013) Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms. Prostate Cancer 2013, pages 1-10.
Crossref
Crossref
Mathieu Gunepin, Florence Derache, Jean-Pierre De Jaureguibery, Jean-Sébastien Bladé, Olivier Gisserot, Olivier Cathelinaud, Benoît Bédrune & Didier Rivière. (2013) Ostéonécroses des maxillaires dues aux bisphosphonates administrés par voie intraveineuse : incidence et facteurs de risque. Médecine Buccale Chirurgie Buccale 19:1, pages 21-31.
Crossref
Crossref
Elizabeth Shane, Sundeep Khosla & David Burr. 2013. Osteoporosis. Osteoporosis
1873
1908
.
Sebastian Kühl, Christian Walter, Stephan Acham, Roland Pfeffer & J. Thomas Lambrecht. (2012) Bisphosphonate-related osteonecrosis of the jaws – A review. Oral Oncology 48:10, pages 938-947.
Crossref
Crossref
Peyman Hadji, Matti Aapro, Luis Costa & Michael Gnant. (2012) Antiresorptive treatment options and bone health in cancer patients—safety profiles and clinical considerations. Cancer Treatment Reviews 38:6, pages 815-824.
Crossref
Crossref
. (2012) Risks for Jaw Osteonecrosis Drastically Increases After 2 Years of Bisphosphonate Therapy. Journal of Evidence Based Dental Practice 12:3, pages 251-253.
Crossref
Crossref
Junro Yamashita & Laurie K. McCauley. (2012) Antiresorptives and Osteonecrosis of the Jaw. Journal of Evidence Based Dental Practice 12:3, pages 233-247.
Crossref
Crossref
Sunday O. Akintoye & Elliot V. Hersh. (2012) Risks for Jaw Osteonecrosis Drastically Increases After 2 Years of Bisphosphonate Therapy. Journal of Evidence Based Dental Practice 12:2, pages 116-118.
Crossref
Crossref
F. Saad, J.E. Brown, C. Van Poznak, T. Ibrahim, S.M. Stemmer, A.T. Stopeck, I.J. Diel, S. Takahashi, N. Shore, D.H. Henry, C.H. Barrios, T. Facon, F. Senecal, K. Fizazi, L. Zhou, A. Daniels, P. Carrière & R. Dansey. (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Annals of Oncology 23:5, pages 1341-1347.
Crossref
Crossref
Ourania Nicolatou-Galitis, Magdalini Migkou, Amanda Psyrri, Aristotle Bamias, Dimitrios Pectasides, Theofanis Economopoulos, Judith E. Raber-Durlacher, George Dimitriadis & Meletios A. Dimopoulos. (2012) Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: Report of 2 cases with clinical implications. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 113:2, pages 234-238.
Crossref
Crossref
Bente Thoft Jensen, Pascale Dielenseger, Lawrence Drudge-Coates, Karen Flynn, Susanne Hieronymi, H.A.M. (Erik) van Muilekom, Ronny Pieters & Lisbeth Bjerregaard Voss. (2012) Taking the lead – Sharing best practice in intravenous bisphosphonate use in urological cancers. European Journal of Oncology Nursing 16:1, pages 42-53.
Crossref
Crossref
Scott E. DelacroixJr.Jr., Christopher G. Wood,Eric Jonasch. 2012. Brenner and Rector's The Kidney. Brenner and Rector's The Kidney
1508
1535
.
Gelsomina L Borromeo, Caroline Brand, John G Clement, Michael McCullough, Wendy Thomson, Elly Flitzanis & John D Wark. (2011) Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study. BMC Musculoskeletal Disorders 12:1.
Crossref
Crossref
Allan Lipton & Ira Jacobs. (2011) Denosumab. Current Opinion in Supportive & Palliative Care 5:3, pages 258-264.
Crossref
Crossref
Tyler Davis, Don-John Summerlin, Michael Moore, Anne Younger & E. Gabriela Chiorean. (2011) Mandibular fracture in a patient treated with long-term antiangiogenic therapy and previous bisphosphonate exposure. Community Oncology 8:9, pages 415-417.
Crossref
Crossref
Nuttapong Ngamphaiboon, Jennifer L. Frustino, Ellen B. Kossoff, Maureen A. Sullivan & Tracey L. O'Connor. (2011) Osteonecrosis of The Jaw: Dental Outcomes in Metastatic Breast Cancer Patients Treated With Bisphosphonates With/Without Bevacizumab. Clinical Breast Cancer 11:4, pages 252-257.
Crossref
Crossref
Michael Pazianas & Bo Abrahamsen. (2011) Safety of bisphosphonates. Bone 49:1, pages 103-110.
Crossref
Crossref
Alison T. Stopeck, Allan Lipton, Jean-Jacques Body, Guenther G. Steger, Katia Tonkin, Richard H. de Boer, Mikhail Lichinitser, Yasuhiro Fujiwara, Denise A. Yardley, María Viniegra, Michelle Fan, Qi Jiang, Roger Dansey, Susie Jun & Ada Braun. (2011) Reply to V. Fusco et al. Journal of Clinical Oncology 29:17, pages e523-e524.
Crossref
Crossref
Filippo Francini, Alessandra Pascucci, Edoardo Francini, Salvatora Tindara Miano, Gianluca Bargagli, Grazia Ruggiero & Roberto Petrioli. (2011) Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab. The Journal of the American Dental Association 142:5, pages 506-513.
Crossref
Crossref
Wataru Mizunoya, Ritika Upadhaya, Frank J. Burczynski, Guqi Wang & Judy E. Anderson. (2011)
Nitric oxide donors improve prednisone effects on muscular dystrophy in the
mdx
mouse diaphragm
. American Journal of Physiology-Cell Physiology 300:5, pages C1065-C1077.
Crossref
Crossref
Luis Arboleya, Mercedes Alperi & Sara Alonso. (2011) Efectos adversos de los bisfosfonatos. Reumatología Clínica 7:3, pages 189-197.
Crossref
Crossref
David H. HenryLuis CostaFrancois GoldwasserVera HirshVania HungriaJana PrausovaGiorgio Vittorio ScagliottiHarm SleeboomAndrew SpencerSaroj Vadhan-RajRoger von MoosWolfgang WillenbacherPenella J. WollJianming WangQi JiangSusie JunRoger DanseyHoward Yeh. (2011) Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. Journal of Clinical Oncology 29:9, pages 1125-1132.
Crossref
Crossref
Jeanny B Aragon-Ching. (2011) Unravelling the role of denosumab in prostate cancer. The Lancet 377:9768, pages 785-786.
Crossref
Crossref
M. Pazianas. (2010) Osteonecrosis of the Jaw and the Role of Macrophages. JNCI Journal of the National Cancer Institute 103:3, pages 232-240.
Crossref
Crossref
Ana O. Hoff, Bela Toth, Mimi Hu, Gabriel N. Hortobagyi & Robert F. Gagel. (2010) Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Annals of the New York Academy of Sciences 1218:1, pages 47-54.
Crossref
Crossref
Luis Arboleya, Mercedes Alperi & Sara Alonso. (2011) Adverse effects of bisphosphonates. Reumatología Clínica (English Edition) 7:3, pages 189-197.
Crossref
Crossref
Alison T. StopeckAllan LiptonJean-Jacques BodyGuenther G. StegerKatia TonkinRichard H. de BoerMikhail LichinitserYasuhiro FujiwaraDenise A. YardleyMaría ViniegraMichelle FanQi JiangRoger DanseySusie JunAda Braun. (2010) Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study. Journal of Clinical Oncology 28:35, pages 5132-5139.
Crossref
Crossref
MA Scheper, R Chaisuparat, KJ Cullen & TF Meiller. (2010) A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis. Fibrogenesis & Tissue Repair 3:1.
Crossref
Crossref
. (2010) Current World Literature. Current Opinion in Supportive & Palliative Care 4:3, pages 207-227.
Crossref
Crossref
Junro Yamashita, Laurie K McCauley & Catherine Van Poznak. (2010) Updates on osteonecrosis of the jaw. Current Opinion in Supportive and Palliative Care 4:3, pages 200-206.
Crossref
Crossref
Cesar Augusto Migliorati, Sook-Bin Woo, Ian Hewson, Andrei Barasch, Linda S. Elting, Fred K. L. Spijkervet & Michael T. Brennan. (2010) A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Supportive Care in Cancer 18:8, pages 1099-1106.
Crossref
Crossref
Catherine Van Poznak. (2010) Osteonecrosis of the jaw and bevacizumab therapy. Breast Cancer Research and Treatment 122:1, pages 189-191.
Crossref
Crossref
Valentina Guarneri, David Miles, Nicholas Robert, Véronique Diéras, John Glaspy, Ian Smith, Christoph Thomssen, Laura Biganzoli, Tanya Taran & PierFranco Conte. (2010) Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Research and Treatment 122:1, pages 181-188.
Crossref
Crossref
Bo Abrahamsen. (2010) Adverse Effects of Bisphosphonates. Calcified Tissue International 86:6, pages 421-435.
Crossref
Crossref
Yang-Min NingJames L. GulleyPhilip M. ArlenSukyung WooSeth M. SteinbergJohn J. WrightHoward L. ParnesJane B. TrepelMin-Jung LeeYeong Sang KimHaihao SunRavi A. MadanLea LathamElizabeth JonesClara C. ChenWilliam D. FiggWilliam L. Dahut. (2010) Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology 28:12, pages 2070-2076.
Crossref
Crossref
Jochen Greiner, Rainer Küfer, Sven N. Reske, Volker Martin, Hartmut Döhner & Mark Ringhoffer. (2010) Metronomic Treatment with Low-Dose Trofosfamide Leads to a Long-Term Remission in a Patient with Docetaxel-Refractory Advanced Metastatic Prostate Cancer. Case Reports in Medicine 2010, pages 1-4.
Crossref
Crossref
Noam Yarom, Sharon Elad, Carlos Madrid & Cesar A. Migliorati. (2010) Osteonecrosis of the jaws induced by drugs other than bisphosphonates – A call to update terminology in light of new data. Oral Oncology 46:1, pages e1.
Crossref
Crossref
E. Serra, M. Paolantonio, G. Spoto, F. Mastrangelo, S. Tetè & M. Dolci. (2009) Bevacizumab-Related Osteneocrosis of the Jaw. International Journal of Immunopathology and Pharmacology 22:4, pages 1121-1123.
Crossref
Crossref
N. Rolfes & G. Lümmen. (2009) Der Stellenwert von Bisphosphonaten in der Therapie des ProstatakarzinomsThe value of biphosphonates in the therapy of prostate cancer. Der Urologe 48:9, pages 990-996.
Crossref
Crossref
Matthew R Allen. (2009) Does rat + bisphosphonate + exposed bone = an animal model of ONJ?. IBMS BoneKEy 6:6, pages 227-231.
Crossref
Crossref
Vera Hirsh. (2009) Metastatic Bone Disease in Patients with Solid Tumors–-Burden of Bone Disease and the Role of Zoledronic Acid. Clinical Medicine. Therapeutics 1, pages CMT.S1958.
Crossref
Crossref